Short bets have risen against consumer discretionary stocks as stimulus efforts have faded, a new S&P Global Market Intelligence report found.
Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Esperion Therapeutics (ESPR) reports mixed second-quarter results as it beats estimates for earnings but misses the same for sales. Stock down.